Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
President 42 -
Corporate Secretary - -
Treasurer 60 -
Director TitleAgeSince
Director/Board Member 42 -
Date Insider Type Main position Quantity % Market Cap.
28/07/20
Armistice Capital LLC
OthersCompany 10,377,161 142.8724%
28/07/20Tender

Chief Executive Officer

21,978 0.3026%
28/07/20Tender

Chief Financial Officer

6,239 0.0859%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.93% - - 16.07M
-1.42%+1.15%+40.94%+157.01% 1,035B
+0.49%+2.95%+52.96%+49.86% 574B
+0.51%-0.96%+16.96%+63.40% 397B
+0.58%+0.77%+21.19%+15.95% 324B
-0.85%-2.86%+22.05%+13.80% 281B
+0.44%+3.48%+24.48%+34.39% 278B
+1.66%+5.61%-44.67%-47.49% 193B
-0.07%+1.34%+19.16%+62.98% 191B
-0.90%-3.56%+11.16%+59.98% 156B
Average +0.02%+1.68%+18.25%+45.54% 381.1B
Weighted average by Cap. -0.27%+2.39%+28.04%+72.07%
Logo Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!